We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+1.53%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$64.8B
AUM Growth
-$1.23B
(-1.9%)
Cap. Flow
+$395M
Cap. Flow
% of AUM
0.61%
Top 10 Holdings %
Top 10 Hldgs %
28.4%
Holding
1,116
New
212
Increased
277
Reduced
389
Closed
160
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$330M |
| 2 |
CTRA
Coterra Energy
CTRA
|
+$214M |
| 3 |
Boston Scientific
BSX
|
+$204M |
| 4 |
RB Global
RBA
|
+$183M |
| 5 |
Chevron
CVX
|
+$131M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$190M |
| 2 |
Royalty Pharma
RPRX
|
+$187M |
| 3 |
Dover
DOV
|
+$178M |
| 4 |
Boeing
BA
|
+$168M |
| 5 |
Devon Energy
DVN
|
+$155M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.24% |
| 2 | Healthcare | 15.45% |
| 3 | Financials | 12.46% |
| 4 | Industrials | 9.23% |
| 5 | Communication Services | 8.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
826
Wyndham Hotels & Resorts
WH
$5.46B
| $2.44M | ﹤0.01% |
+30,000
| New | +$2.35M |
|
827
NET Power
NPWR
$125M
| $2.4M | ﹤0.01% |
1,540,000
| – | – |
|
828
Replimune Group
REPL
$814M
| $2.35M | ﹤0.01% |
307,368
-1,500,000
| -83% | -$11.5M |
|
829
PMV Pharmaceuticals
PMVP
$66.1M
| $2.31M | ﹤0.01% |
+1,860,000
| New | +$2.37M |
|
830
Moog Inc Class A
MOG.A
$13B
| $2.21M | ﹤0.01% |
7,553
| – | – |
|
|
MRX
831
Marex Group Limited Ordinary Shares
MRX
$4.72B
| $2.14M | ﹤0.01% |
48,107
-1,257,348
| -96% | -$49.7M |
|
|
MSLE
832
Satellos Bioscience
MSLE
$204M
| $2.14M | ﹤0.01% |
+380,354
| New | +$3.74M |
|
|
NXDR
833
Nextdoor Holdings
NXDR
$835M
| $2.1M | ﹤0.01% |
1,500,000
| – | – |
|
834
Hormel Foods
HRL
$13.9B
| $2.04M | ﹤0.01% |
90,146
-173,000
| -66% | -$4.14M |
|
835
Burford Capital
BUR
$907M
| $2.03M | ﹤0.01% |
+450,000
| New | +$3.94M |
|
836
Macerich
MAC
$7.32B
| $1.98M | ﹤0.01% |
+105,000
| New | +$1.99M |
|
837
Neumora Therapeutics
NMRA
$276M
| $1.95M | ﹤0.01% |
+1,000,000
| New | +$2.59M |
|
838
Cogent Biosciences
COGT
$6.79B
| $1.92M | ﹤0.01% |
50,000
-50,000
| -50% | -$1.85M |
|
839
American Financial Group
AFG
$11.9B
| $1.92M | ﹤0.01% |
15,000
-305,694
| -95% | -$39.7M |
|
840
Personalis
PSNL
$1.26B
| $1.91M | ﹤0.01% |
+300,000
| New | +$2.53M |
|
841
Lumentum
LITE
$59.4B
| $1.9M | ﹤0.01% |
+2,703
| New | +$1.48M |
|
842
Alliant Energy
LNT
$19.4B
| $1.89M | ﹤0.01% |
26,308
-54,800
| -68% | -$3.78M |
|
843
Adicet Bio
ACET
$72.8M
| $1.87M | ﹤0.01% |
274,375
| – | – |
|
844
Zevra Therapeutics
ZVRA
$563M
| $1.86M | ﹤0.01% |
200,000
-75,000
| -27% | -$676K |
|
845
Hilton Worldwide
HLT
$74B
| $1.79M | ﹤0.01% |
5,900
-25,900
| -81% | -$7.85M |
|
846
Cooper Companies
COO
$13.7B
| $1.78M | ﹤0.01% |
24,860
-154,600
| -86% | -$12.2M |
|
847
ProMIS Neurosciences
PMN
$109M
| $1.77M | ﹤0.01% |
+139,275
| New | +$2.08M |
|
848
BrightSpring Health Services
BTSG
$14.3B
| $1.69M | ﹤0.01% |
+39,730
| New | +$1.6M |
|
|
CMPS
849
Compass Pathways
CMPS
$1.52B
| $1.66M | ﹤0.01% |
+300,000
| New | +$2.02M |
|
850
Cincinnati Financial
CINF
$28.3B
| $1.65M | ﹤0.01% |
10,469
-40,431
| -79% | -$6.57M |
|
Similar funds
Adage Capital Partners's Q1 2026 Portfolio in Review
As of Q1 2026, Adage Capital Partners held 1,116 positions worth $64.8B, down 1.9% from $66.1B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Adage Capital Partners's Q1 2026 filing shows 212 new, 277 increased, 389 reduced and 160 closed positions. Its largest new stake was Takeda Pharmaceutical: 6,424,984 shares worth $119M. The largest sale was Avidity Biosciences, an estimated $190M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 29% a quarter earlier, followed by Healthcare and Financials.
- Adage Capital Partners's largest Q1 2026 buy was Takeda Pharmaceutical: 6,424,984 shares worth $119M.
- Adage Capital Partners added most to Revolution Medicines in Q1 2026, an estimated $330M increase.
- Adage Capital Partners's biggest Q1 2026 reduction was Royalty Pharma, cutting an estimated $187M.
- Adage Capital Partners fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
- Adage Capital Partners's ten largest holdings make up 28% of its $64.8B portfolio in Q1 2026.
- Adage Capital Partners opened 212 new positions and closed 160 in Q1 2026.
- Adage Capital Partners's portfolio value fell 1.9% quarter-over-quarter to $64.8B.
Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.